VABeachBio Innovation Challenge
  • Home
  • Overview
    • Key Dates
    • Phase 0 - Enter Challenge
    • Phase 1 - Elevator Speech
    • Phase 2 - Business Plan
    • Phase 3 - Start-up
    • Training Topics
  • About Us
    • Contact Us
    • Testimonials
    • News
  • Home
  • Overview
    • Key Dates
    • Phase 0 - Enter Challenge
    • Phase 1 - Elevator Speech
    • Phase 2 - Business Plan
    • Phase 3 - Start-up
    • Training Topics
  • About Us
    • Contact Us
    • Testimonials
    • News
Search by typing & pressing enter

YOUR CART

BACK TO INVENTION LIST

Treatment for the Cure of Type I Diabetes
Patent Numbers:
  • US 14/773/497
  • CN 201480022386.4
  • CA 2,904,586
  • EPC 14760521.6
  • PCT/US2017/052849
  • US 8,603,472
  • US 8,609,091
  • US 7,744,876
  • US 8,603,471

Executive Summary:
  • Invention Type: Therapeutic
  • Patent Status: Active
  • Representative Patent Link: https://patents.google.com/patent/US8603472B2/
  • Research Institute: University of Missouri
  • Disease Focus:  Type I Diabetes
  • Basis of Invention: Therapeutic protein + endothelial cell progenitors
  • How it works: Type I Diabetes occurs when the immune system destroys the insulin-producing β-cells of the pancreatic islets. Administration of a chimeric Ig-GAD2 protein eliminates the self reactive T-cells responsible for destruction of the β-cells and allows recovery from pre-diabetic insulinitis and hyperglycemia. Co-administration of the Ig-GAD2 protein with endothelial cell progenitors enables full recovery from overt Type I Diabetes through restoration of the pancreatic islet β-cells as well as the surrounding endothelial cells.
  • Lead Challenge Inventor: Habib Zaghouani
  • Development Stage: Pre-clinical (mouse data)
  • Novelty:
    • Therapeutic Ig-GAD2 protein therapy alone or in conjunction with the administration of endothelial cell progenitors for the treatment of and full recovery from Type I Diabetes
  • Clinical Applications:
    • Application of this therapy can prevent or reverse Type I Diabetes
 
General Description:
Type I Diabetes (T1D) is an autoimmune disease caused by the destruction of the body’s insulin-producing pancreatic islet β-cells. T1D affects millions of Americans, with over 40,000 new diagnoses each year. Current treatments address the symptoms of the disease by supplementing insulin by injection; a treatment requiring constant management and multiple daily injections. Technology developed by Habib Zaghouani at the University of Missouri lays the foundation for a cure to the underlying cause of T1D, through reversal of the autoimmune response and subsequent recovery of the natural insulin-producing pancreatic islet β-cells.
 
Strengths:
  • Ig-GAD2 treatment demonstrated in mouse models of T1D to prevent the onset of T1D through recovery of pancreatic islet β-cells through the pre-diabetic stages of insulinitis and hyperglycemia
  • Ig-GAD2 treatment in conjunction with the administration of endothelial cell progenitors demonstrated as a functional cure to overt T1D in mouse models of T1D through recovery of pancreatic islet β-cells and their surrounding endothelial cells
 
Patent Status:
  • Multiple issued and pending patents
 
Inventor Bio: Habib Zaghouani
https://medicine.missouri.edu/faculty/habib-zaghouani-phd/
Powered by Create your own unique website with customizable templates.